Search research articles
Contact Us
Filters
Showing results (211-220 of 226) with videos related to
Page
of 23
Sort By:
The Journal of Infection
|
March 16, 2026
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Acta Neuropathologica
|
March 29, 2021
Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration
Lynn van Olst, Carla Rodriguez-Mogeda, Carmen Picon, et al.
The Journal of Infection
|
February 20, 2025
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Cellular and Molecular Life Sciences : CMLS
|
November 2, 2022
Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms
Simon G Royce, Paul V Licciardi, Raymond C Beh, et al.
Frontiers in Immunology
|
May 8, 2026
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults
Nadia Mazarakis, Zheng Quan Toh, Tsetsegsaikhan Batmunkh, et al.
Clinical & Translational Immunology
|
October 4, 2024
Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection
Zheng Quan Toh, Jeremy Anderson, Nadia Mazarakis, et al.
Vaccine
|
October 10, 2025
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
Tsetsegsaikhan Batmunkh, Eleanor F G Neal, Otgonjargal Amraa, et al.
The Lancet Regional Health. Western Pacific
|
February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Tsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology
|
April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
Tsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
JAMA Network Open
|
March 9, 2022
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Zheng Quan Toh, Jeremy Anderson, Nadia Mazarakis, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 226) with videos related to
Sort By:
Page
of 23
The Journal of Infection
|
March 16, 2026
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Acta Neuropathologica
|
March 29, 2021
Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration
Lynn van Olst, Carla Rodriguez-Mogeda, Carmen Picon, et al.
The Journal of Infection
|
February 20, 2025
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
Nadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.
Cellular and Molecular Life Sciences : CMLS
|
November 2, 2022
Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms
Simon G Royce, Paul V Licciardi, Raymond C Beh, et al.
Frontiers in Immunology
|
May 8, 2026
Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults
Nadia Mazarakis, Zheng Quan Toh, Tsetsegsaikhan Batmunkh, et al.
Clinical & Translational Immunology
|
October 4, 2024
Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS-CoV-2 Omicron infection
Zheng Quan Toh, Jeremy Anderson, Nadia Mazarakis, et al.
Vaccine
|
October 10, 2025
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
Tsetsegsaikhan Batmunkh, Eleanor F G Neal, Otgonjargal Amraa, et al.
The Lancet Regional Health. Western Pacific
|
February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
Tsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology
|
April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial
Tsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
JAMA Network Open
|
March 9, 2022
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Zheng Quan Toh, Jeremy Anderson, Nadia Mazarakis, et al.
Page
of 23